Royal Bank of Canada
AVBP icon

Royal Bank of Canada’s ArriVent BioPharma AVBP Stock Holding History

Royal Bank of Canada’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1K Sell
44
-937
-96% -$21.2K ﹤0.01% 6978
2025
Q4 		$21K Sell
981
-16,813
-94% -$350K ﹤0.01% 6021
2025
Q3 		$328K Buy
17,794
+17,770
+74,042% +$349K ﹤0.01% 4770
2025
Q2 		$1K Sell
24
-120
-83% -$2.49K ﹤0.01% 6948
2025
Q1 		$3K Sell
144
-1,608
-92% -$39.4K ﹤0.01% 6536
2024
Q4 		$47K Sell
1,752
-1,714
-49% -$49.2K ﹤0.01% 5737
2024
Q3 		$81K Buy
3,466
+2,539
+274% +$57.6K ﹤0.01% 5477
2024
Q2 		$17K Buy
927
+558
+151% +$9.95K ﹤0.01% 6141
2024
Q1 		$7K Buy
+369
New +$7.44K ﹤0.01% 6358

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Royal Bank of Canada's AVBP Position: Q1 2026 in Review

Royal Bank of Canada reduced its ArriVent BioPharma (AVBP) stake by 96% in Q1 2026, selling an estimated $21.2K and leaving 44 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #6978.

Royal Bank of Canada first reported a position in AVBP in Q1 2024 and has held it in 9 quarters since. The position peaked at $328K in Q3 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Royal Bank of Canada held 44 shares of ArriVent BioPharma worth $1K as of Q1 2026.
  • Royal Bank of Canada sold 937 ArriVent BioPharma shares in Q1 2026, an estimated $21.2K.
  • ArriVent BioPharma made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6978 holding.
  • Royal Bank of Canada first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 9 quarters since.
  • Royal Bank of Canada's ArriVent BioPharma position peaked at $328K in Q3 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.